MRI contrast developer Epix Pharmaceuticals of Lexington, MA, has resubmitted a new drug application (NDA) for its MR angiography (MRA) contrast agent, Vasovist (gadofosveset trisodium).
Vasovist is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through MRA.
The agent has been approved for marketing in 33 countries, including the European Union, Switzerland, Turkey, Australia, and Canada. If approved in the U.S., Vasovist would become the first contrast agent in the country for use with MRA.
Related Reading
Epix president resigns, May 29, 2008
Epix to resubmit NDA for Vasovist, April 24, 2008
Epix reaches agreement with FDA over Vasovist, February 1, 2008
Epix to raise $16.3 million, November 12, 2007
Epix receives FDA response, June 19, 2007
Copyright © 2008 AuntMinnie.com
